Aggressive combination chemotherapy of bone @entity236 in childhood XXXX containing aclacinomycin-A: a multicentric trial.

@entity1 @entity981 @entity137 @entity712 @entity8253 @entity296 @entity548 @entity221 @entity3136 @entity344 @entity236 @entity204 @entity166
An intensive 7-day combination chemotherapy protocol was designed to reinduce @entity1 with early bone @entity236 of @entity981 (less than 6 months after the end of or during preceding treatment). This aggressive approach seemed to be justified for a group of @entity1 who were at the highest risk for ultimate treatment failure. In all, 38 @entity1 were enrolled for study. The ratio of male (median age, 10 years) to female (median age, 13 years) subjects was 27:11. Thirty @entity1 were treated for their first relapse and eight for their second or subsequent relapse. Isolated bone marrow involvement was present in 24 cases. All @entity1 had received heavy pretreatment including @entity8253 with cumulative doses of between 120 and 240 mg/m2. 22 of these @entity1 , achieved complete remission, ten did not respond to therapy, and six died from the @entity137 of the protocol. @entity712 was the cause of @entity204 in one @entity1 (after additional radiotherapy for a mediastinal mass). No further clinical manifestation of @entity296 could be observed. The other five @entity1 died from @entity548 or @entity166 complications. The main side effects were @entity221 , @entity344 , @entity3136 , and severe @entity236 lasting for about 2 weeks with nadirs of platelets and white blood count around days 10-14. The remission rate of 60% was acceptable, though not satisfactory. Only four @entity1 survived disease-free for 13+, 14+, 20+, and 22+ months after diagnosis of relapse.
